Publication: Direct oral anticoagulants in asian patients with atrial fibrillation: Consensus recommendations by the Asian Pacific Society of Cardiology on strategies for thrombotic and bleeding risk management
Issued Date
2021-01-01
Resource Type
ISSN
17583764
17583756
17583756
Other identifier(s)
2-s2.0-85108117546
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
European Cardiology Review. Vol.16, (2021)
Suggested Citation
Daniel T.T. Chong, Felicita Andreotti, Peter Verhamme, Jamshed J. Dalal, Noppacharn Uaprasert, Chun Chieh Wang, Young Keun On, Yi Heng Li, Jun Jiang, Koji Hasegawa, Khalid Almuti, Rong Bai, Sidney T.H. Lo, Rungroj Krittayaphong, Lai Heng Lee, David K.L. Quek, Sofian Johar, Swee Chong Seow, Christopher J. Hammett, Jack W.C. Tan Direct oral anticoagulants in asian patients with atrial fibrillation: Consensus recommendations by the Asian Pacific Society of Cardiology on strategies for thrombotic and bleeding risk management. European Cardiology Review. Vol.16, (2021). doi:10.15420/ECR.2020.43 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/78702
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Direct oral anticoagulants in asian patients with atrial fibrillation: Consensus recommendations by the Asian Pacific Society of Cardiology on strategies for thrombotic and bleeding risk management
Author(s)
Daniel T.T. Chong
Felicita Andreotti
Peter Verhamme
Jamshed J. Dalal
Noppacharn Uaprasert
Chun Chieh Wang
Young Keun On
Yi Heng Li
Jun Jiang
Koji Hasegawa
Khalid Almuti
Rong Bai
Sidney T.H. Lo
Rungroj Krittayaphong
Lai Heng Lee
David K.L. Quek
Sofian Johar
Swee Chong Seow
Christopher J. Hammett
Jack W.C. Tan
Felicita Andreotti
Peter Verhamme
Jamshed J. Dalal
Noppacharn Uaprasert
Chun Chieh Wang
Young Keun On
Yi Heng Li
Jun Jiang
Koji Hasegawa
Khalid Almuti
Rong Bai
Sidney T.H. Lo
Rungroj Krittayaphong
Lai Heng Lee
David K.L. Quek
Sofian Johar
Swee Chong Seow
Christopher J. Hammett
Jack W.C. Tan
Other Contributor(s)
Siriraj Hospital
National Hospital Organization Kyoto Medical Center
Cleveland Clinic Abu Dhabi
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Beijing Anzhen Hospital, Capital Medical University
Chang Gung University College of Medicine
Raja Isteri Pengiran Anak Saleha Hospital
National University Hospital
Zhejiang University School of Medicine
Royal Brisbane and Women's Hospital
Chulalongkorn University
KU Leuven
Singapore General Hospital
SKKU School of Medicine
Pantai Holdings Sdn Bhd
National Heart Centre, Singapore
National Cheng King University Hospital
Sengkang General Hospital
Kokilaben Hospital
Liverpool Hospital
National Hospital Organization Kyoto Medical Center
Cleveland Clinic Abu Dhabi
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Beijing Anzhen Hospital, Capital Medical University
Chang Gung University College of Medicine
Raja Isteri Pengiran Anak Saleha Hospital
National University Hospital
Zhejiang University School of Medicine
Royal Brisbane and Women's Hospital
Chulalongkorn University
KU Leuven
Singapore General Hospital
SKKU School of Medicine
Pantai Holdings Sdn Bhd
National Heart Centre, Singapore
National Cheng King University Hospital
Sengkang General Hospital
Kokilaben Hospital
Liverpool Hospital
Abstract
The disease burden of AF is greater in Asia-Pacific than other areas of the world. Direct oral anticoagulants (DOACs) have emerged as effective alternatives to vitamin K antagonists (VKA) for preventing thromboembolic events in patients with AF. The Asian Pacific Society of Cardiology developed this consensus statement to guide physicians in the management of AF in Asian populations. Statements were developed by an expert consensus panel who reviewed the available data from patients in Asia-Pacific. Consensus statements were developed then put to an online vote. The resulting 17 statements provide guidance on the assessment of stroke risk of AF patients in the region, the appropriate use of DOACs in these patients, as well as the concomitant use of DOACs and antiplatelets, and the transition to DOACs from VKAs and vice versa. The periprocedural management of patients on DOAC therapy and the management of patients with bleeding while on DOACs are also discussed.